XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB) received a delist determination from The Nasdaq Stock Market on May 18 after the company failed to file its annual report, a violation that could remove its shares from the major exchange. The notice escalates the pressure on the Israel-based drug developer, which has not yet submitted its Form 20-F for the fiscal year that ended over four months ago.
"The Company...has received a letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC, dated May 18, 2026, notifying the Company that since the Company has not yet filed its Annual Report on Form 20-F for the year ended December 31, 2025, it no longer complies with Nasdaq's Listing Rule 5250(c)(1)," XTL Biopharmaceuticals said in a press release.
The specific rule requires companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Failure to comply can result in delisting, a move that would shift XTLB shares to the less liquid over-the-counter (OTC) markets, making it significantly harder for the company to attract institutional investment and raise future capital.
The notice to XTL is not an isolated event, but rather part of a broader wave of compliance enforcement by Nasdaq in May 2026. In the same week, agricultural technology firm Agroz Inc. (AGRZ) and biopharma company Anavex Life Sciences (AVXL) both disclosed receiving similar notices for late filings. Other firms have been cited for different violations, highlighting a potential crackdown on listing standards.
Nasdaq's recent enforcement actions have spanned multiple rules and industries. On May 21, Liminatus Pharma (LIMN) announced it faces delisting for failing to meet the $50 million market value of listed securities requirement. A day later, E-Power Inc. (EPOW) reported a notice for its shares trading below the minimum $1.00 bid price for 30 consecutive business days.
For companies like XTL and Agroz, which received notices for late filings, Nasdaq provides a path to regain compliance. Agroz noted it has 60 days to submit a compliance plan, and if accepted, could be granted an extension of up to 180 days. XTL did not specify its next steps in its announcement. The pattern suggests that while Nasdaq is actively enforcing its rules, it also provides a structured process for companies to resolve the deficiencies.
This article is for informational purposes only and does not constitute investment advice.
